ki:elements Publishes New Validation Results on Remote Speech Biomarker for Cognition (SB-C) in Early Alzheimer's Disease

ki:elementsDigital speech biomarker company ki:elements has published validation results on the use of its ki:e speech biomarker for cognition (SB-C) in early Alzheimer’s disease in the "Karger - Digital Biomarkers" journal.(1)

Two European dementia studies - the Dutch DeepSpA study in collaboration with Maastricht University & the Scottish SPeAK study in collaboration with University of Edinburgh - helped to validate the psychometric properties of the SB-C. Results demonstrate the ki:e SB-C's ability to differentiate subjective complaints from people with mild cognitive impairment, and its ability to track decline towards Mild Cognitive Impairment in early phases of the disease within a year. On a construct level the SB-C score is correlated with established measures for cognition and its domain scores are anchored around established assessments for neurocognitive functions such as learning and memory, executive function and processing speed. In the longitudinal DeepSpA study the SB-C shows also good test-retest reliability. Validation followed the V3 approach championed by the Digital Medicine Society (DiMe).

Prof. Craig Ritchie, Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention at the University of Edinburgh, and PI of the SpEAK study commented: "Early detection of AD is the prerequisite for prevention. These results show that speech is a scalable and sensitive screening tool that could be a key building block in ending AD."

Dr. Johannes Tröger, Chief Scientific Officer of ki:elements added: "We are pleased with these validation results in early AD, validating that SB-C is a reliable measure of cognition - usable in clinical trials and healthcare. In parallel, we are working on studies validating the SB-C in even earlier, preclinical stages of the disease."

About ki:elements and SB-C

ki:elements GmbH is pioneering the research and development of novel digital speech biomarkers. The ki:e speech biomarker for cognition (SB-C) is a speech based cognitive digital biomarker that takes fifteen minutes to complete, can be administered remotely and automatically. It is used in academic and pharmaceutical research as a scalable cognition measurement and screening tool.

For more information, visit https://ki-elements.de

1. Tröger J, Baykara E, Zhao J, ter Huurne D, Possemis N, Mallick E, Schäfer S, Schwed L, Mina M, Linz N, Ramakers I, Ritchie C.
Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework.
Digit Biomark 2022;6:107-116. doi: 10.1159/000526471

Most Popular Now

ChatGPT Shows 'Impressive' Acc…

A new study led by investigators from Mass General Brigham has found that ChatGPT was about 72 percent accurate in overall clinical decision making, from coming up with possible diagnoses...

WiFi SPARK's Healthcare Business Re…

Leading WiFi provider WiFi SPARK is rebranding its healthcare arm as SPARK Technology Services Limited. The new identity marks the completion of the integration of the former Hospedia bedside unit...

Online AI-Based Test for Parkinson'…

An artificial intelligence (AI) tool developed by researchers at the University of Rochester can help people with Parkinson's disease remotely assess the severity of their symptoms within minutes. A study...

ChatGPT is Debunking Myths on Social Med…

ChatGPT could help to increase vaccine uptake by debunking myths around jab safety, say the authors of a study published in the peer-reviewed journal Human Vaccines and Immunotherapeutics. The researchers asked...

AI Performs Comparably to Human Readers …

Using a standardized assessment, researchers in the UK compared the performance of a commercially available artificial intelligence (AI) algorithm with human readers of screening mammograms. Results of their findings were...

Siemens Healthineers Expands Production …

Siemens Healthineers is expanding its site in Rudolstadt, Germany. By mid 2024, a new manufacturing building will be built on the site. The new manufacturing plant will produce electron accelerators...

More Cases of Breast Cancer Detected wit…

One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet Digital...

ChatGPT Performs as Well as Doctors for …

The artificial intelligence chatbot ChatGPT performed as well as a trained doctor in suggesting likely diagnoses for patients being assessed in emergency medicine departments, in a pilot study to be...

Smartphone Technology Expected to Advanc…

Since the 1980s, we have known that neurological soft signs (NSS) can distinguish people with schizophrenia from psychiatrically healthy individuals. NSS are subtle neurological impairments that principally manifest as decreased...

AI may Outperform Most Humans at Creativ…

Large language model (LLM) artificial intelligence (AI) chatbots may be able to outperform the average human at a creative thinking task where the participant devises alternative uses for everyday objects...

MEDICA 2023 + COMPAMED 2023: "Where…

13 - 16 November 2023, Düsseldorf, Germany. The medical technology market is in worldwide motion and the signs ahead of MEDICA 2023 and COMPAMED 2023 in Düsseldorf as the internationally leading...

AI and Machine Learning can Successfully…

Artificial intelligence (AI) and machine learning (ML) can effectively detect and diagnose Polycystic Ovary Syndrome (PCOS), which is the most common hormone disorder among women, typically between ages 15 and...